search
Back to results

Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases (BLEND-II)

Primary Purpose

Spinal Neoplasms, Neoplasm Metastasis, Radiosurgery

Status
Withdrawn
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
SBRT followed by surgical stabilization within 24-48 hours
Sponsored by
UMC Utrecht
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participation in PRESENT cohort
  • Painful radiosensitive metastases from solid tumors in the cervical, thoracic or lumbar spine needing surgical stabilization
  • Histologic proof of malignancy or radiographic/clinical characteristics indicating malignancy beyond reasonable doubt
  • Radiographic evidence of spinal metastases
  • Fit for (radio)surgery
  • Age > 18 years at the time of given informed consent in the PRESENT cohort.
  • Written informed consent

Exclusion Criteria:

  • SBRT cannot be delivered, e.g. in patients who cannot lie on the treatment table because of pain
  • Surgery cannot be performed, e.g. in patients with multiple spinal metastases that cannot be bridged
  • Previous surgery or radiotherapy to index lesion
  • Neurological deficits (ASIA C, B or A)
  • Partial neurological deficits (ASIA D) with rapid progression (hours to days)
  • Non-ambulatory patients
  • Patient in hospice or with < 3 months life expectancy
  • Medically inoperable or patient refused surgery
  • Radiosensitizing systemic treatment that cannot reasonably be stopped (for example immunotherapy and EGFR inhibitors)

Sites / Locations

  • UMC Utrecht

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SBRT followed by surgical stabilization within 48 hours

Arm Description

SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.

Outcomes

Primary Outcome Measures

Pain response
Pain response is defined as a decrease in initial worst pain score by at least 2 points on a Numeric Rating Scale (NRS) of 10 at the treated site, without increase in analgesic use, or an analgesic decrease of at least 25% without an increase in pain score

Secondary Outcome Measures

Duration of pain relief
Duration of pain relief, as measured by the Brief Pain Inventory (BPI)
Length of hospital stay
Length of hospital stay in days
30-day mortality
Mortality after 30 days
Neurological status
American Spinal Injury Association (ASIA) scale as measured by physical examination of neurologists or trained ASIA physician
Neurological deterioration
Defined as a deterioration on the American Spinal Injury Association (ASIA) scale of more than one level
Adverse events
Adverse events will be scored using a SAVES form

Full Information

First Posted
August 6, 2021
Last Updated
May 16, 2023
Sponsor
UMC Utrecht
search

1. Study Identification

Unique Protocol Identification Number
NCT05060653
Brief Title
Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases
Acronym
BLEND-II
Official Title
Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases: Cohort Study According to the IDEAL Recommendations
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Alternative study was set up
Study Start Date
October 2022 (Anticipated)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UMC Utrecht

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to assess pain response after combining stereotactic body radiotherapy (SBRT) and pedicle screw fixation in a 48-hour window for the treatment of painful unstable metastases of the thoracic and/or lumbar spine.
Detailed Description
Rationale Sixty-five percent of cancer patients with terminal illness have bone metastases, with debilitating pain often as the severe consequence. The spine is the most common location for bone metastases. Standard treatment of unstable vertebral metastases consists of stabilizing surgery, followed by external beam radiotherapy after two weeks. Although this approach is effective in 60-70% of patients, it is has several downsides. Firstly, because of the two weeks interval between surgery and external beam radiotherapy, necessary for sufficient wound healing, it takes time before radiotherapy-induced pain relief is achieved. Moreover, the surgical implants used cause scatter artifacts on planning computed tomography images which prohibits high-resolution imaging and accurate targeting of the lesion. Multiple hospital visits (ranging from 1 to 10) are needed for administration of external beam irradiation, and in about 30-40% of patients no adequate pain response is achieved. An alternative treatment strategy, which would lead to faster pain relief in a higher proportion of patients with less hospital visits, would be highly desirable from the patient's perspective. Secondly, this strategy delays the start of systemic therapy. Objective The main outcome of this study is pain response 4 weeks after start of the treatment. Study design Prospective cohort study nested within the PRESENT cohort being a phase 2b study according to the IDEAL recommendations Study population All patients, male and female, with impending spinal instability requiring surgical intervention and radiotherapy at the University Medical Center Utrecht Intervention The combined treatment of stereotactic body radiotherapy and pedicle screw fixation in a 24 to 48-hour window for the treatment of painful unstable metastases of the cervical, thoracic and/or lumbar spine. Main study parameters/endpoints The main outcome of this study is pain response after 4 weeks Nature and extent of the burden and risks associated with participation, benefit and group relatedness In the preceding BLEND First-in-man study, the investigators have observed no Serious Adverse Events after a median follow-up of 13 months demonstrating the safety and feasibility of this approach.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Neoplasms, Neoplasm Metastasis, Radiosurgery, Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SBRT followed by surgical stabilization within 48 hours
Arm Type
Experimental
Arm Description
SBRT and surgical stabilization will be performed within a 24 to 48-hour time window instead of today's standard of care of two weeks between surgical stabilization and conventional radiotherapy.
Intervention Type
Other
Intervention Name(s)
SBRT followed by surgical stabilization within 24-48 hours
Intervention Description
In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
Primary Outcome Measure Information:
Title
Pain response
Description
Pain response is defined as a decrease in initial worst pain score by at least 2 points on a Numeric Rating Scale (NRS) of 10 at the treated site, without increase in analgesic use, or an analgesic decrease of at least 25% without an increase in pain score
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Duration of pain relief
Description
Duration of pain relief, as measured by the Brief Pain Inventory (BPI)
Time Frame
Through hospital stay, an average of 3 days
Title
Length of hospital stay
Description
Length of hospital stay in days
Time Frame
Through hospital stay, an average of 3 days
Title
30-day mortality
Description
Mortality after 30 days
Time Frame
30 days
Title
Neurological status
Description
American Spinal Injury Association (ASIA) scale as measured by physical examination of neurologists or trained ASIA physician
Time Frame
Through hospital stay, an average of 3 days
Title
Neurological deterioration
Description
Defined as a deterioration on the American Spinal Injury Association (ASIA) scale of more than one level
Time Frame
Through hospital stay, an average of 3 days
Title
Adverse events
Description
Adverse events will be scored using a SAVES form
Time Frame
Through hospital stay, an average of 3 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participation in PRESENT cohort Painful radiosensitive metastases from solid tumors in the cervical, thoracic or lumbar spine needing surgical stabilization Histologic proof of malignancy or radiographic/clinical characteristics indicating malignancy beyond reasonable doubt Radiographic evidence of spinal metastases Fit for (radio)surgery Age > 18 years at the time of given informed consent in the PRESENT cohort. Written informed consent Exclusion Criteria: SBRT cannot be delivered, e.g. in patients who cannot lie on the treatment table because of pain Surgery cannot be performed, e.g. in patients with multiple spinal metastases that cannot be bridged Previous surgery or radiotherapy to index lesion Neurological deficits (ASIA C, B or A) Partial neurological deficits (ASIA D) with rapid progression (hours to days) Non-ambulatory patients Patient in hospice or with < 3 months life expectancy Medically inoperable or patient refused surgery Radiosensitizing systemic treatment that cannot reasonably be stopped (for example immunotherapy and EGFR inhibitors)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jorrit-Jan Verlaan, MD, PhD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
Facility Information:
Facility Name
UMC Utrecht
City
Utrecht
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD may be shared when requested through the principal investigator

Learn more about this trial

Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases

We'll reach out to this number within 24 hrs